🇺🇸 FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11566015

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

CRINETICS PHARMACEUTICALS, INC. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559564

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548890

HPK1 antagonists and uses thereof

Nimbus Saturn, Inc. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548887

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504426

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505585

FcRn antagonists and methods of use

The Board of Regents of the University of Texas System · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472772

S1P3 antagonists

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11466010

Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof

The Regents of the University of Colorado, a Body Corporate · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464830

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11452723

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC · Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11434268

Vascular endothelial growth factor antagonists

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11351177

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11344557

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11337971

Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11337988

Use of ouabain antagonists to inhibit viral infection

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11311549

Corticotropin releasing factor receptor antagonists

SPRUCE BIOSCIENCES, INC. · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306150

Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

Five Prime Therapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11299476

Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use the

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11253572

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11247969

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11229681

Dominant-negative FGF2 antagonists

The Regents of the University of California · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11214621

Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagon

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208397

Small molecule antagonists of sumo related modification of CRMP2 and uses thereof

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11202784

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted